Arcturus Therapeutics Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $15.02
- Today's High:
- $15.74
- Open Price:
- $15.74
- 52W Low:
- $11.7
- 52W High:
- $31.41
- Prev. Close:
- $15.88
- Volume:
- 662100
Company Statistics
- Market Cap.:
- $425.15 million
- Book Value:
- 5.499
- Revenue TTM:
- $51.50 million
- Operating Margin TTM:
- -285.28%
- Gross Profit TTM:
- $12.36 million
- Profit Margin:
- -284.78%
- Return on Assets TTM:
- -25.22%
- Return on Equity TTM:
- -72.46%
Company Profile
Arcturus Therapeutics Holdings Inc had its IPO on 2020-04-16 under the ticker symbol ARCT.
The company operates in the Healthcare sector and Biotechnology industry. Arcturus Therapeutics Holdings Inc has a staff strength of 177 employees.
Stock update
Shares of Arcturus Therapeutics Holdings Inc opened at $15.74 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $15.02 - $15.74, and closed at $15.39.
This is a -3.09% slip from the previous day's closing price.
A total volume of 662,100 shares were traded at the close of the day’s session.
In the last one week, shares of Arcturus Therapeutics Holdings Inc have increased by +1.72%.
Arcturus Therapeutics Holdings Inc's Key Ratios
Arcturus Therapeutics Holdings Inc has a market cap of $425.15 million, indicating a price to book ratio of 3.4283 and a price to sales ratio of 9.3831.
In the last 12-months Arcturus Therapeutics Holdings Inc’s revenue was $51.50 million with a gross profit of $12.36 million and an EBITDA of $-145634000. The EBITDA ratio measures Arcturus Therapeutics Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Arcturus Therapeutics Holdings Inc’s operating margin was -285.28% while its return on assets stood at -25.22% with a return of equity of -72.46%.
In Q3, Arcturus Therapeutics Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 448.6%.
Arcturus Therapeutics Holdings Inc’s PE and PEG Ratio
- Forward PE
- 2.8604
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-5.7 per share while it has a forward price to earnings multiple of 2.8604 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arcturus Therapeutics Holdings Inc’s profitability.
Arcturus Therapeutics Holdings Inc stock is trading at a EV to sales ratio of 6.9215 and a EV to EBITDA ratio of -2.5022. Its price to sales ratio in the trailing 12-months stood at 9.3831.
Arcturus Therapeutics Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $293.63 million
- Total Liabilities
- $75.85 million
- Operating Cash Flow
- $-2186000.00
- Capital Expenditure
- $1.81 million
- Dividend Payout Ratio
- 0%
Arcturus Therapeutics Holdings Inc ended 2023 with $293.63 million in total assets and $0 in total liabilities. Its intangible assets were valued at $293.63 million while shareholder equity stood at $145.67 million.
Arcturus Therapeutics Holdings Inc ended 2023 with $5.18 million in deferred long-term liabilities, $75.85 million in other current liabilities, 26000.00 in common stock, $-455488000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $237.68 million and cash and short-term investments were $237.68 million. The company’s total short-term debt was $27,702,000 while long-term debt stood at $32.04 million.
Arcturus Therapeutics Holdings Inc’s total current assets stands at $246.68 million while long-term investments were $0.00 and short-term investments were $0. Its net receivables were $2.04 million compared to accounts payable of $17.96 million and inventory worth $0.
In 2023, Arcturus Therapeutics Holdings Inc's operating cash flow was $-2186000.00 while its capital expenditure stood at $1.81 million.
Comparatively, Arcturus Therapeutics Holdings Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $15.39
- 52-Week High
- $31.41
- 52-Week Low
- $11.7
- Analyst Target Price
- $39.83
Arcturus Therapeutics Holdings Inc stock is currently trading at $15.39 per share. It touched a 52-week high of $31.41 and a 52-week low of $31.41. Analysts tracking the stock have a 12-month average target price of $39.83.
Its 50-day moving average was $18.12 and 200-day moving average was $17.24 The short ratio stood at 6.91 indicating a short percent outstanding of 0%.
Around 1386.1% of the company’s stock are held by insiders while 8201.2% are held by institutions.
Frequently Asked Questions About Arcturus Therapeutics Holdings Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Arcturus Therapeutics Holdings Inc. operates as a late-stage clinical mRNA medicines and vaccines company. Its technologies include LUNAR lipid-mediated delivery; STARR mRNA Technology (samRNA); and mRNA drug substance. The company’s pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis with partnered programs, including glycogen storage disease type III and hepatitis B virus. Its RNA therapeutics platforms can be applied in multiple types of nucleic acid medicines, including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Its technologies are covered by its patent portfolio, including patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. The company was founded in 2013 and is headquartered in San Diego, California.